Abstract
One obstacle in treating pre-existing parental tumors by vaccination with cytokine gene-modified tumor cells is the impaired expression of immune-related molecules such as MHC class I. In this study, to enhance MHC class I expression on pre-inoculated parental tumors, low dose TNF (300 U, 500 U, 1000 U), that is, TNF at levels shown to cause neither tumor regression nor any severe adverse reaction, was systemically injected into parental tumors bearing mice before vaccination with TNF gene-modified Meth-A cells or B-16 cells. Since the class I expression was confirmed to continue for at least 24 h following administration of TNF, TNF was administered 6 h before vaccination. Complete regression of relatively large parental tumors (M0) (8.0-10.0 mm in diameter) was observed in five of eight mice treated with 1000 U TNF, partial regression was observed in mice treated with 500 U, and a lesser yet significant regression was observed in mice treated with only 300 U. Contrarily, in the mice which had received vaccination without the TNF pretreatment, no complete regression was observed. This effect was inhibited with the anti-class I antibody or anti-CD8 antibody. Growth of a re-established, B16 tumor was significantly suppressed wit...Continue Reading
References
Nov 1, 1991·Japanese Journal of Cancer Research : Gann·Y ItohY Niitsu
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H GammF Herrmann
Jul 9, 1991·International Journal of Cancer. Journal International Du Cancer·A J BeniersJ A Schalken
Jan 1, 1990·Cancer Immunology, Immunotherapy : CII·F VánkyE Klein
Jul 1, 1990·Clinical and Experimental Immunology·M C KuppnerN de Tribolet
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·Y WatanabeT Sakata
Jan 1, 1989·Cancer Immunology, Immunotherapy : CII·T MoritzC G Schmidt
Sep 1, 1987·Infection and Immunity·J BartholeynsC Galanos
Oct 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·P LindahlI Gresser
Apr 1, 1995·Cellular Immunology·E A Ranheim, T J Kipps
Sep 27, 1995·International Journal of Cancer. Journal International Du Cancer·Y KoshitaS Sakamaki
Sep 27, 1995·International Journal of Cancer. Journal International Du Cancer·K KurodaM Kato
May 1, 1995·British Journal of Cancer·Y TsutsumiT Mayumi
Feb 1, 1995·Cancer Immunology, Immunotherapy : CII·Y ItohY Niitsu
Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·G DranoffR C Mulligan
Mar 1, 1994·Japanese Journal of Cancer Research : Gann·S FujiiY Niitsu
Oct 1, 1996·Human Gene Therapy·Y SatoY Nitsu
Apr 10, 1997·International Journal of Cancer. Journal International Du Cancer·E JägerA Knuth
Jan 1, 1997·Annual Review of Immunology·U BoehmJ C Howard
Nov 21, 1998·The Tohoku Journal of Experimental Medicine·S SuzukiT Nukiwa
Citations
Aug 29, 2003·Molecular Immunology·R E Kast
Feb 1, 2003·Vaccine·Michal SmahelVladimír Vonka
May 16, 2009·Cancer Gene Therapy·R R Weichselbaum, D Kufe
Mar 17, 2006·Cell Research·Dajing XiaJim Xiang
Oct 29, 2008·Acta Pharmacologica Sinica·Xia Wang, Yong Lin
Jan 12, 2012·PloS One·Tiphanie DurfortJean-Christophe François
May 16, 2008·Biomedical Research·Takahiro SuzukiHiroshi Kijima
Aug 30, 2007·Immunology·Jasper ManningMilan Reinis
Sep 1, 2015·Translational Research : the Journal of Laboratory and Clinical Medicine·Jeremy T-H ChangR Stephanie Huang
Mar 13, 2003·World Journal of Gastroenterology : WJG·Jin-Kun ZhangSu-Biao Chen
Jan 26, 2008·Molecular Endocrinology·Kosj YamoahEtsuko Abe
Aug 23, 2006·Cytotherapy·Z YanY Zhang